Disease · MONDO_0001741

hyperparathyroidism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hyperparathyroidism. Diseases, record MONDO_0001741. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001741

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hyperparathyroidism; Open Targets
Open Targets ID: MONDO_0001741; Open Targets
Other names: Elevated blood parathyroid hormone level; Open Targets
Disease Ontology: DOID:13543; Disease Ontology
MeSH: D006961; MeSH
NCI Thesaurus: C48259; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 10 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PARICALCITOL	CHEMBL1200622	Small molecule	Approval	TTD	2	1	1	Drugs and targets
CINACALCET	CHEMBL1201284	Small molecule	Approval	EMA Human Drugs and TTD	4	0	0	Drugs and targets
ETELCALCETIDE	CHEMBL3545184	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ASP7991	CHEMBL3545100		Phase 2	TTD	1	0	0	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Unknown	ClinicalTrials.gov	3	3	3	Drugs and targets
ALUMINUM HYDROXIDE	CHEMBL1200706	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CALCIUM ACETATE	CHEMBL1200800	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CHOLECALCIFEROL	CHEMBL1042	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
RISEDRONIC ACID	CHEMBL923	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
SEVELAMER	CHEMBL5314349	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CASR	Extracellular calcium-sensing receptor	3	Calcium sensing receptor agonist; Calcium sensing receptor positive allosteric modulator	Approval	https://conductscience.org/library/genes/846	Drugs and targets
VDR	Vitamin D3 receptor	3	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
FDPS	Farnesyl pyrophosphate synthase	1	Farnesyl diphosphate synthase inhibitor	Unknown	https://conductscience.org/library/genes/2224	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00587158	Oral Paricalcitol in Kidney Transplant Recipients	Not applicable	100	2013-05-08	Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary	PARICALCITOL	Its record names the disease	ClinicalTrials.gov
NCT03960437	The Effect of Etelcalcetide on CKD-MBD	Phase 2	22	2023-09-21	Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal	ETELCALCETIDE	Its record names the disease	ClinicalTrials.gov
NCT01672047	Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients	Not applicable	350		Chronic Kidney Disease, Vitamin D Deficiency	ERGOCALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT05347082	Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment	Not applicable	47		Postmenopausal Osteoporosis, Postmenopause, Hyperparathyroidism, Secondary, Hypovitaminosis D, Hyperparathyroidism, Primary	CHOLECALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT05346419	Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients	Not applicable	33		Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism	ERGOCALCIFEROL, RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01426724	Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease	Not applicable	0		Chronic Kidney Disease, Secondary Hyperparathyroidism	ERGOCALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT00018135	Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals	Not applicable			Renal Failure	ALUMINUM HYDROXIDE, CALCIUM ACETATE, SEVELAMER	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Immunosuppression Without Paricalcitol (Control) vs Immunosuppression With Paricalcitol: Number of Subjects With Hyperparathyroidism at One Year	31 of 49	15 of 51	100	NCT00587158	Trial comparisons
Immunosuppression Without Paricalcitol (Control) vs Immunosuppression With Paricalcitol: serious adverse events	16 of 49	27 of 51	100	NCT00587158	Trial comparisons
Immunosuppression Without Paricalcitol (Control) vs Immunosuppression With Paricalcitol: Number of Subjects Who Died or Lost Their Renal Graft During First Year	0 of 44	1 of 43	87	NCT00587158	Trial comparisons
Immunosuppression Without Paricalcitol (Control) vs Immunosuppression With Paricalcitol: Number of Subjects With Osteopenia/Osteoporosis of the Lumbar Spine at One Year	9 of 43	14 of 42	85	NCT00587158	Trial comparisons
Immunosuppression Without Paricalcitol (Control) vs Immunosuppression With Paricalcitol: Number of Subjects With Osteopenia/Osteoporosis of the Hip at One Year	9 of 42	12 of 41	83	NCT00587158	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40576086	DERIVED	1	PubMed
37574661	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001741

GET https://conductscience.org/api/diseases/v1/MONDO_0001741/drugs

API reference For AI assistants